LONDON, UK / ACCESSWIRE / October 11, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Compugen Ltd (NASDAQ: CGEN), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/'symbol=CGEN. The Company announced on October 09, 2017, the disclosure of positive research results indicating the potential of CGEN-15032 as a target for the development of first-in-class cancer therapy. The research was performed in collaboration with the Johns Hopkins University (JHU) School of Medicine, and suggests that CGEN-15032 may serve as an immuno-suppressive target within the tumor microenvironment. For immediate access to our complimentary reports, including today's coverage, register for free now at:
http://protraderdaily.com/register/
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on CGEN. Go directly to your stock of interest and access today's free coverage at:
http://protraderdaily.com/optin/'symbol=CGEN
Compugen Extends Multi-Year Immuno-Oncology Research Collaboration with JHU
The Company also announced the extension of its multi-year immuno-oncology research collaboration with JHU to include new additional targets discovered by Compugen which have the potential to serve as a basis for the development of cancer immunotherapy treatments.
Compugen entered into the research collaboration with JHU in December 2014. The collaboration focused on the evaluation of selected novel B7/CD28-like immune checkpoint candidates discovered by Compugen for the potential treatment of cancer.
Collaboration Provides Access to World-Class Immuno-Oncology Knowledge
Commenting on the disclosure of the positive research results, Anat Cohen-Dayag, PhD, President and Chief Executive Officer of Compugen, mentioned that the data the Company has achieved with CGEN-15032, together with JHU, exemplifies the tremendous value of its collaboration, providing access to world-class immuno-oncology knowledge and expertise to successfully develop its immuno-oncology programs, and accelerate its path towards future human testing.
CGEN-15032 Presented at International Cancer Immunotherapy Conference
News releases suggests that the computational discovery and experimental validation of CGEN-15032 as a novel target for cancer immunotherapy was subject of both an oral and a poster presentation at the 3rd annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, held in September 2017 in Mainz/Frankfurt, Germany.
About CGEN-15032
CGEN-15032 is a novel myeloid and epithelial immuno-oncology target discovered by Compugen's immune checkpoint discovery platform. CGEN-15032 is expressed on cancer cells and subsets of myeloid cells within the tumor microenvironment. Addressing the immuno-suppressive environment of the tumor through myeloid drug targets has the potential for developing treatments that may expand the patient population responsive to current treatments.
About Compugen Ltd
Founded in 1993, Compugen, a predictive drug discovery and development of first-in-class therapeutics for cancer immunotherapy Company, has a unique, broadly applicable, predictive discovery infrastructure, which is advancing a therapeutic pipeline aimed at harnessing the immune system to eradicate cancer. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen is headquartered in Holon, Israel.
Last Close Stock Review
On Tuesday, October 10, 2017, the stock closed the trading session at $3.95, climbing 3.95% from its previous closing price of $3.80. A total volume of 265.92 thousand shares have exchanged hands, which was higher than the 3-month average volume of 111.74 thousand shares. Compugen's stock price surged 21.54% in the last one month and 5.33% in the previous three months. The stock currently has a market cap of $201.97 million.
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@protraderdaily.com
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily
